Al Hajj et al. made the first demonstration that the fractionated CD44+/CD24− subpopulation from breast cancer patients exhibited a 100-fold greater capacity to form tumors (i.e., tumorigenicity) compared to those unsorted cells after transplantation into mammary pad of immunodeficient mice [16]. The gene discussed is CD44; the disease is breast carcinoma.